期刊文献+

LOX-1在吡格列酮调节高脂血症大鼠主动脉凋亡蛋白表达中的作用 被引量:1

Role of LOX-1 in Pioglitazone Regulating Apoptosis Protein in Aorta of Hyperlipidemia Rats
暂未订购
导出
摘要 目的:观察吡格列酮对高脂血症大鼠主动脉血凝集素样氧化低密度脂蛋白受体-1(LOX-1)和凋亡蛋白Bax、Bcl-2表达的影响,探讨LOX-1在其中的变化和作用。方法:清洁级SD大鼠26只,随机分为正常组(n=9)、高脂饲料组(n=17),高脂饲料喂养12周后再随机分为高脂血症模型组(n=8)和吡格列酮组(n=9),分别给予生理盐水(正常组和模型组)和药物(吡格列酮组)干预4周后,常规方法检测各组血脂水平,免疫组织化学法检测各组主动脉LOX-1、Bax、Bcl-2蛋白表达,TUNEL染色法观察主动脉内膜细胞凋亡情况,并计算细胞凋亡指数(AI)。结果:高脂饲料喂养12周后,成功复制17只高脂血症模型大鼠。吡格列酮干预4周后,与模型组比较,吡格列酮组甘油三酯(TG)、胆固醇(TC)水平明显降低(P<0.01)。与正常组相比,模型组大鼠主动脉LOX-1、Bax蛋白表达明显增加(P<0.01),Bcl-2蛋白表达及Bcl-2/Bax比值明显降低(P<0.01);与模型组相比,吡格列酮组主动脉LOX-1、Bax蛋白表达明显降低(P<0.01),Bcl-2蛋白表达和Bcl-2/Bax比值明显升高(P<0.01),且吡格列酮组主动脉内膜AI亦较模型组显著降低(P<0.01)。结论:吡格列酮可改善高脂血症大鼠血脂水平,调节凋亡蛋白表达,减少主动脉内皮细胞凋亡,其作用可能与其下调LOX-1蛋白表达有关。 Objective:To investigate influence of pioglitazone on the expression of LOX-1 and Bax,Bcl-2 on aorta in hyperlipidemia rats,and also to study the effects of LOX-1.Method:26 male SD rats were randomly divided into control group(n=9) and high-fat diets group(n=17).High-fat diets rats raised for 12 weeks were randomly divided into model group(n=8) and pioglitazone treated group(n=9),respectively gavaged with distilled water and pioglitazone.After 4 weeks,serum lipid level of all rats was measured.LOX-1 and apoptosis protein of Bax,Bcl-2 on the aorta were analyzed by immunohistochemical method.Terminal deoxynucleotidyl acyltransferase-mediated dUTP nick end labeling stained apoptotic cells in aortic intimal area to calculate apoptosis index.Results:After 12 weeks,17 rats raised with high-fat diets were successfully induced hyperlipidemia animal models.Intervention with pioglitazone for 4 weeks,compared with model group,serem levels of TG,TC were decreased(P0.01).Compare with control group,the expression of LOX-1 and Bax protein on aorta were significantly increased(P0.01),the Bcl-2 protein and ratio of Bcl-2/Bax was markedly decreased in model group(P0.01).On the other hand,compare with model group,the expression of LOX-1 and Bax protein were lower,the Bcl-2 protein and ratio of Bcl-2/Bax were prominently higher in the pioglitazone treated group,moreover apoptotic index of aortic intima was significantly lower than the model group.Conclusion:Pioglitazone improves lipid levels in hyperlipidemia rats,which has an effect on expression of apoptosis protein Bax,Bcl-2 in aorta,reducing aortic endothelial cell apoptosis.This maybe have a relation to LOX-1 lowed.
出处 《微循环学杂志》 2012年第2期17-20,100,I0001,共6页 Chinese Journal of Microcirculation
基金 中国博士后科学基金资助项目(20090461491)
关键词 吡格列酮 高脂血症 血凝集素样氧化低密度脂蛋白受体-1 内皮细胞凋亡 动脉粥样硬化 Pioglitazone Hyperlipidemia Lectin-like oxidized low-density lipoprotein receptor-1 Endothelial cells Apoptosis Atherosclerosis
  • 相关文献

参考文献14

  • 1Mehta JL,Chen J,Hermonat PL,et al.Lectin-like,oxidized low-density lipoprotein receptor-1(LOX-1):a critical player in the development of atherosclerosis and related disorders[J].Cardiovasc Res,2006,69(1):36-45.
  • 2Morawietz H.LOX-1receptor as a novel target in endothelial dysfunction and atherosclerosis[J].Dtsch Med Wochenschr,2010,135(7):308-312.
  • 3杨杨,戚筠,谢军,叶跃青,刘志平,邢晓磊,姚春红,白如君,邱宇珍.吡格列酮对初诊2型糖尿病患者血脂水平的影响及临床意义[J].微循环学杂志,2011,21(1):30-31. 被引量:7
  • 4Erdmann E,Wilcox R.Pioglitazone and mechanisms of CV protection[J].QJM,2010,103(4):213-228.
  • 5Hasty AH,Gruen ML,Terry ES,et al.Effects of vitamin E on oxidative stress and atherosclerosis in an obese hyperlipidemic mouse model[J].J Nutr Biochem,2007,18(2):127-133.
  • 6Rodriguez C,Slevin M,Rodriguez-Calvo R,et al.Modulation of endothelium and endothelial progenitor cell function by low-density lipoproteins:implication for vascular repair,angiogenesis and vasculogenesis[J].Pathobiology,2009,76(1):11-22.
  • 7Sawamura T,Kume N,Aoyama T,et al.An endothelial receptor for oxidized low-density lipoprotein[J].Nature,1997,386(6620):73-77.
  • 8Sakurai K,Sawamura T.Stress and vascular responses:endothelial dysfunction via lectin-like oxidized low-density lipoprotein receptor-1:close relationships with oxidative stress[J].J Pharmacol Sci,2003,91(3):182-186.
  • 9Otsui K,Kakutani M,Yuasa K,et al.Calcium-dependent platelet aggregation through the interaction between phosphatidylserine and LOX-1[J].Cardiovasc Res,2010,88(3):547-547.
  • 10Fratta Pasini A,Garbin U,Cominacini L.Inhibition of lectinlike oxidized low-density lipoprotein receptor-1expression:is it right now a safe and promising therapeutic approach for atherosclerosis[J].J Hypertens,2009,27(3):452-455.

二级参考文献11

  • 1Jeninga EH,Bugge A,Nielsen R,et al.Peroxisome proliferator-activated receptor gamma regulates expression of the anti-lipolytic G-protein-coupled receptor 81 (GPR81/Gpr81).J Biol Chem,2009,284(39):26 385-26 393.
  • 2Yki-Jarvinen H.Thiazolidinediones.N Engl J Med,2004,351(11):1 106-1 118.
  • 3Goldberg RB,Kendall DM,Deeg MA,et al.A Comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.Diabetes Gare,2005,28(7):1 547-1 554.
  • 4陈灏珠.实用内科学(第12版,上册).北京:人民卫生出版社.2006:1 026.
  • 5Masato Y,Hiroki E,Yuichi N,et al.Life style-related diseases of the digestive system:gene expression in nonalcoholic steatohepati-tis patients and treatment strategies.J Pharmacol Sci,2007,105(2):151-156..
  • 6Irons BK,Greene RS,Mazzolini TA,et al.Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.Pharmacotherapy,2006,26(2):168-181.
  • 7Motawi TM,Hashem RM,Rashed LA,et al.Comparative study between the effect of the peroxisome proliferator activated receptor-alpha ligands fenofibrate and n-3 polyunsaturated fatty acids on activation of 5'-AMP-activated protein kinase-alpha1 in high-fat fed rats.J Pharm Pharmacol,2009,61(10):1 339-1 346.
  • 8Beysen C,Murphy EJ,Nagaraja H,et al.A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipognesis in type 2 diabetes.Lipid Res,2008,49(12):2 657-2 663.
  • 9Tilden DP,Mariz S,O'Bryan-Tear G,et al.A lifetime modelled economic evaluation comparing pioglitazoneand rosiglitazone for the treatmentof Type 2 diabetes mellitus in the UK.Pharmacoeconomics,2007,25 (1):39-54.
  • 10Fisher M.Improving cardiovascular risk-applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.Int J Clin Pract,2009,63(9):1 354-1 368.

共引文献6

同被引文献1

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部